umu.sePublikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Safety and efficacy of atorvastatin in patients with severe renal dysfunction
Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Medicin.
Umeå universitet, Medicinska fakulteten, Institutionen för folkhälsa och klinisk medicin, Medicin.
Vise andre og tillknytning
2005 (engelsk)Inngår i: Scandinavian Journal of Urology and Nephrology, ISSN 0036-5599, E-ISSN 1651-2065, Vol. 39, nr 6, s. 503-510Artikkel i tidsskrift (Fagfellevurdert) Published
sted, utgiver, år, opplag, sider
2005. Vol. 39, nr 6, s. 503-510
Emneord [en]
Cholesterol, dialysis, high-density lipoprotein, lipids, low-density lipoprotein, risk factors, triglycerides
HSV kategori
Identifikatorer
URN: urn:nbn:se:umu:diva-16044PubMedID: 16303728OAI: oai:DiVA.org:umu-16044DiVA, id: diva2:155717
Tilgjengelig fra: 2007-08-16 Laget: 2007-08-16 Sist oppdatert: 2018-06-09bibliografisk kontrollert
Inngår i avhandling
1. Analysis of risk factors in patients with severe chronic kidney disease. The role of atorvastatin.
Åpne denne publikasjonen i ny fane eller vindu >>Analysis of risk factors in patients with severe chronic kidney disease. The role of atorvastatin.
2013 (engelsk)Doktoravhandling, med artikler (Annet vitenskapelig)
Abstract [en]

Background and aim: There had been no randomized end-point studies with statins for patients with severe renal failure. The purpose of this prospective, open, randomized, controlled study was to investigate whether atorvastatin (10 mg/day) would alter cardiovascular end-points and the overall mortality rate of patients with chronic kidney disease stage 4 or 5 (creatinine clearance</30 ml/min) and to influence risk factors.

Material & Methods: This was an open, prospective, randomized study. A total of 143 patients were included: 73 were controls and 70 were prescribed 10 mg/day of atorvastatin. As efficacy variables, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and triglyceride levels were determined at the start of the study and at 1, 3, 6, 12, 18, 24, 30 and 36 months. The primary end-points were all cause of mortality, non-lethal acute myocardial infarction, and coronary artery intervention. Various risk factors were studied. In the 97 patients on haemodialysis inter dialysis weight gain (IDWG) was calculated as ultrafiltration in kg/body weight in kg given in percentage of the weight. The burden of IDWG was analyzed.

Results: In the atorvastatin group, total cholesterol and low-density lipoprotein cholesterol were significantly reduced, the latter by 35% at 1 month and then sustained. Atorvastatin was withdrawn in 23% of patients due to unacceptable side effects, most frequent complaints being gastrointestinal discomfort and headache. Primary end-points occurred in 74% of the subjects. There was no difference in cardiovascular endpoint and survival between the control and atorvastatin groups. The 5-year end-point-free survival rate from study entry was 20%. There was no evidence of more benefit of atorvastatin for patients with diabetes mellitus and chronic kidney disease versus the other patients; instead plasma fibrinogen increased. The IDWG was significantly larger in patients who suffered from end-points due to cardiovascular reasons, cardiac reasons, congestive heart failure, aortic aneurysm, and intracerebral bleeding.

Conclusion: These data showed that in contrast to other patient groups, patients with severe chronic kidney disease 4 and 5, including those with diabetes mellitus, seem to have no benefit from 10mg/day of atorvastatin. Instead we found a high IDWG to be an important risk factor that should be prevented. There was no evident connection between atorvastatin medication and IDWG.

sted, utgiver, år, opplag, sider
Umeå: Umeå universitet, 2013. s. 86
Serie
Umeå University medical dissertations, ISSN 0346-6612 ; 1574
Emneord
Atorvastatin, cholesterol, chronic kidney disease, haemodialysis, cholesterol, lipids, peritoneal dialysis, risk factors, statins, inter dialysis weight gain
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-68682 (URN)978-91-7459-554-3 (ISBN)
Disputas
2013-05-30, Sal E04, by 6E, Norrlands universitetssjukhus, Umeå, 09:00 (svensk)
Opponent
Veileder
Tilgjengelig fra: 2013-05-02 Laget: 2013-04-23 Sist oppdatert: 2018-06-08bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

PubMed

Personposter BETA

Holmberg, BennyLundberg, LennartStegmayr, Bernd

Søk i DiVA

Av forfatter/redaktør
Holmberg, BennyLundberg, LennartStegmayr, Bernd
Av organisasjonen
I samme tidsskrift
Scandinavian Journal of Urology and Nephrology

Søk utenfor DiVA

GoogleGoogle Scholar

pubmed
urn-nbn

Altmetric

pubmed
urn-nbn
Totalt: 291 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf